Results 1 to 10 of about 1,866 (169)

Bimekizumab Impact on Patient-Reported Outcomes in Patients With Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results From BE HEARD I&II [PDF]

Dermatology and Therapy
Introduction Hidradenitis suppurativa (HS) symptoms (pain, itch, odour and drainage) impair quality of life (QoL). Bimekizumab, a humanised IgG1 monoclonal antibody, selectively inhibits interleukin (IL)-17A and IL-17F.
Hadar Lev-Tov, Koremasa Hayama, Linnea Thorlacius   +2 more
exaly   +4 more sources

Review of bimekizumab in the treatment of psoriasis

Human Vaccines & Immunotherapeutics, 2022
Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these ...
Sindhuja Koppu, Rohan Singh, Kiranjit Kaur, Steven R. Feldman   +3 more
doaj   +4 more sources

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Psoriasis: Targets and Therapy, 2022
Angelo Ruggiero, Luca Potestio, Elisa Camela Snr, Gabriella Fabbrocini, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of ...
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini   +2 more
exaly   +4 more sources

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL [PDF]

RMD Open
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double ...
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya   +17 more
doaj   +5 more sources

Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Meta-Analysis of Randomized Clinical Trials

Therapeutic Advances in Chronic Disease, 2023
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis.
Hong Fang, Jianjun Qiao, Yuqian Wang
exaly   +3 more sources

Efficacy and Safety of Bimekizumab in Elderly Patients: Real-World Multicenter Retrospective Study – IL PSO (Italian Landscape Psoriasis) [PDF]

Journal of Dermatological Treatment
Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis.
Martina Burlando, Tommaso Bianchelli, Luca Potestio   +2 more
exaly   +6 more sources

Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

Journal of Dermatological Treatment, 2023
Aim This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis. Methods The PubMed, Web of Science, Cochrane Library, and Embase databases were systematically searched until November 20, 2022, to identify randomized controlled ...
Yuanyuan Qiu, Yang Zhu, Yun Liu, Qiliang Liu   +3 more
doaj   +3 more sources

Bimekizumab Efficacy and Safety in Japanese Patients With Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Dermatology and Therapy, 2023
Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study.
Mamitaro Ohtsuki, Akimichi Morita
exaly   +2 more sources

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives [PDF]

Patient Preference and Adherence, 2023
Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, Lluís Puig Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainCorrespondence: Gemma Camiña-Conforto, Department of Dermatology, Hospital de la Santa Creu i Sant ...
Camiña-Conforto G, Mateu-Arrom L, López-Ferrer A, Puig L   +3 more
doaj   +2 more sources

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Drugs in Context, 2021
Bimekizumab, a humanized monoclonal IgG1 antibody being currently evaluated for multiple immune-mediated diseases, is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021.
Egídio Freitas, Tiago Torres
doaj   +1 more source